Advertisement
Canada markets closed

  • S&P/TSX

    21,875.79
    -66.37 (-0.30%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CAD/USD

    0.7312
    +0.0011 (+0.15%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • Bitcoin CAD

    82,468.82
    -1,691.17 (-2.01%)
     

  • CMC Crypto 200

    1,282.52
    -1.31 (-0.10%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • RUSSELL 2000

    2,047.69
    +9.35 (+0.46%)
     

  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     

  • NASDAQ

    17,732.60
    -126.08 (-0.71%)
     

  • VOLATILITY

    12.44
    +0.20 (+1.63%)
     

  • FTSE

    8,164.12
    -15.56 (-0.19%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • CAD/EUR

    0.6820
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

STOCKS WOBBLE AFTER COOLING U.S. PCE DATA RAISE FED HOPES

Fed's preferred inflation gauge shows prices rose at slowest pace since March 2021

Why Icon PLC (ICLR) is a Top Value Stock for the Long-Term

Zacks Equity Research
·2 min read

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Why Investors Should Pay Attention to This Value Stock

Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.

ADVERTISEMENT

Icon PLC (ICLR)

Founded in Dublin, Ireland, in 1990, ICON Public Limited Company (“ICON plc”) is a clinical research organization (CRO). The company is a provider of outsourced development and services to pharmaceutical, biotechnology, medical device and government and public health organizations.

ICLR is a Zacks Rank #2 (Buy) stock, with a Value Style Score of B and VGM Score of B. Shares are currently trading at a forward P/E of 21.2X for the current fiscal year compared to the Medical Services industry's P/E of 19.2X. Additionally, ICLR has a PEG Ratio of 1.4 and a Price/Cash Flow ratio of 16.4X. Value investors should also note ICLR's Price/Sales ratio of 3.2X.

A company's earnings performance is important for value investors as well. For fiscal 2024, seven analysts revised their earnings estimate higher in the last 60 days for ICLR, while the Zacks Consensus Estimate has increased $0.11 to $15.07 per share. ICLR also holds an average earnings surprise of 0.8%.

ICLR should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ICON PLC (ICLR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research